Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Virless is a branded formulation of the antiviral drug acyclovir, a synthetic guanine nucleoside analogue used primarily for the treatment and prophylaxis of herpes simplex virus (HSV) infections and varicella-zoster virus (VZV) infections such as chickenpox and herpes zoster. As an oral or topical antiviral, acyclovir is selectively phosphorylated by viral thymidine kinase in infected cells and subsequently converted to its active triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination when incorporated into viral DNA, thereby blocking viral DNA synthesis and replication. Clinically, Virless (acyclovir) is indicated for mucocutaneous and genital HSV infections, suppression and prophylaxis of recurrent HSV particularly in immunocompromised patients, and treatment of varicella and herpes zoster, with dosing adjusted for age, renal function, and immune status.[1][5][7][11][15][17]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Virless.